Malmström H - Search Results

1

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.

Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Héron JF, Bolis G, Malmström H, Malfetano J, Scarabelli C, Vennin P, Ross G, Fields SZ. Gore M, et al. Among authors: malmstrom h. J Clin Oncol. 2001 Apr 1;19(7):1893-900. doi: 10.1200/JCO.2001.19.7.1893. J Clin Oncol. 2001. PMID: 11283120 Clinical Trial.

2

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Bookman MA, et al. Among authors: malmstrom h. J Clin Oncol. 1998 Oct;16(10):3345-52. doi: 10.1200/JCO.1998.16.10.3345. J Clin Oncol. 1998. PMID: 9779711 Clinical Trial.

3

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. ten Bokkel Huinink W, et al. Among authors: malmstrom h. J Clin Oncol. 1997 Jun;15(6):2183-93. doi: 10.1200/JCO.1997.15.6.2183. J Clin Oncol. 1997. PMID: 9196130 Clinical Trial.

4

No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.

Zackrisson AL, Malmström H, Peterson C. Zackrisson AL, et al. Among authors: malmstrom h. Eur J Clin Pharmacol. 2002 May;58(2):103-8. doi: 10.1007/s00228-002-0434-9. Epub 2002 Apr 5. Eur J Clin Pharmacol. 2002. PMID: 12012141 Clinical Trial.

5

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.

Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H. Sorbe B, et al. Among authors: malmstrom h. Int J Oncol. 2012 Mar;40(3):773-81. doi: 10.3892/ijo.2011.1286. Epub 2011 Dec 7. Int J Oncol. 2012. PMID: 22159569 Clinical Trial.

6

Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.

Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H. Sorbe B, et al. Among authors: malmstrom h. Int J Gynecol Cancer. 2012 Jan;22(1):47-53. doi: 10.1097/IGC.0b013e318234fa3a. Int J Gynecol Cancer. 2012. PMID: 22193643 Clinical Trial.

7

Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.

Malmström H, Rasmussen S, Simonsen E. Malmström H, et al. Gynecol Oncol. 1993 May;49(2):166-71. doi: 10.1006/gyno.1993.1101. Gynecol Oncol. 1993. PMID: 8504983 Clinical Trial.

8

A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.

Malmström H, Simonsen E, Westberg R. Malmström H, et al. Gynecol Oncol. 1994 Jan;52(1):20-5. doi: 10.1006/gyno.1994.1005. Gynecol Oncol. 1994. PMID: 8307496 Clinical Trial.

9

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

Sørensen P, Høyer M, Jakobsen A, Malmström H, Havsteen H, Bertelsen K. Sørensen P, et al. Among authors: malmstrom h. Gynecol Oncol. 2001 Apr;81(1):58-62. doi: 10.1006/gyno.2000.6089. Gynecol Oncol. 2001. PMID: 11277650 Clinical Trial.

10

Invasive cancer of the vulva.

Rosén C, Malmström H. Rosén C, et al. Among authors: malmstrom h. Gynecol Oncol. 1997 May;65(2):213-7. doi: 10.1006/gyno.1997.4662. Gynecol Oncol. 1997. PMID: 9159327

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

201 results

Search Page